SlideShare a Scribd company logo
FDA Notificationsand Medwatch Form Requirements
Adverse Event Reporting for
OTC Drugs and Dietary
Supplements
The Background– What YouNeedto Know
Adverse Event (AE) reporting
regulations implement the Dietary
Supplement & OTC Drug
Consumer Protection Act of 2006
(Public Law 109-462).
FDA regulations for adverse
event reporting went into effect in
December 2007. Product label
must contain the address (street
address or P.O. Box) or phone
number at which company or
other responsible person will
receive a serious adverse event
report.
Serious Adverse Event (SAE)
reporting is required for all OTC
Drugs and Dietary
Supplements.
Products That Are Covered
All OTC monographed drugs (Rx to
OTC drugs are already required to
report AEs).
All dietary supplements including
vitamins, minerals, herbal or other
botanical products, amino acids, or
any dietary substance used to
supplement the diet by increasing the
total dietary intake.
When the Personal Care Products
Safety Act becomes law, cosmetics will
also be covered.
Death: Report if the
patient’s death is
suspected of being
associated with use of
the product by the
patient.
Life-Threatening: Report
if the person was at
substantial risk of dying
at time of the adverse
event or if suspected
that continued use of
product could result in a
person’s death.
Hospitalization: Report if
admission to the hospital
was caused by or related
to an adverse event
associated with use of
the product. Emergency
Room treatment is
sometimes reported too.
Disability: Report if the
adverse event resulted in
a significant or
permanent change,
impairment or damage
to the person’s body
function/structure or
quality of life.
Spontaneous abortion,
congenital anomaly or
birth defect associated
with a product use must
also be reported to the
FDA.
Definition of a Serious Adverse Event (SAE)
Section 761(a)(2) of the F,D, & C Act
FDA Notifications- Voluntary SAE Reporting
FDA encourages healthcare
professionals to report serious
adverse events to the agency
for tracking purposes.
FDA’s Center for Food Safety &
Applied Nutrition (CFSAN)
Adverse Event Reporting
System (CAERS) collects reports
about adverse events and
product complaints related to
CFSAN regulated products,
including foods, dietary
supplements and cosmetics.
CFSAN encourages voluntary AE
reports for cosmetics and
conventional foods.
If a company receives a report
of a serious adverse event, you
should report it to CAERS even
if reporting isn’t mandatory for
the product (e.g. a food or
cosmetic).
FDA Notifications
Many serious adverse
events are reported to FDA
directly by consumers,
hospitals, or healthcare
professionals.
If FDA receives a serious
adverse event report about
a company’s product they
will contact you and you
must keep that report on
file. Often FDA notification
comes with a request for
more information and
submission of a Medwatch
form with product label.
MedwatchFormRequirements(Form 3500A)
Medwatch form must identify the injured person (name, age, sex, full address, etc.). Initials
are used to protect privacy.
An identifiable initial reporter of the event.
Identity and contact information for the responsible party (i.e. the manufacturer, packer,
or distributor representative submitting the AE report to FDA).
Name of the specific product that is suspected of causing the adverse event (not just a
brand name).
Description of the serious adverse event with outcome.
Address for MedwatchFormHard Copy
Submission
DIETARY SUPPLEMENTS: FAX NUMBER FOR ALL AEs:
1 800 332 - 0178
FDA Center Food Safety & Nutrition
Office of Food Defense, HFS -11
5100 Paint Brach Parkway
College Park, MD. 20740
OTC DRUGS:
FDA Center Drug Evaluation & Research
Central Document Room
5901-B Ammendale Road
Beltsville, MD. 20705-1266
Online Reportingof MedwatchForms
Or http://www.fda.gov/Safety/MedWatch/default.htm
Go to the FDA
website
(www.fda.gov), click
on “Drugs” and enter
“MEDWATCH form”.
Click on “Download
form” or click on
“Recalls & Alerts”
and see bullet called
“MEDWATCH.”
Click on “Report
serious adverse
events online.”
Thank You
Fororganizationaltrainingonadverseevent
reportingandFDA compliance,visit
www.complianceonline.com.

More Related Content

What's hot

Australia’s Response to COVID-19
Australia’s Response to COVID-19Australia’s Response to COVID-19
Australia’s Response to COVID-19
EMMAIntl
 
US, EU & Japan GMP Requirements: Practical ICH Area Differences & Healthcare ...
US, EU & Japan GMP Requirements: Practical ICH Area Differences & Healthcare ...US, EU & Japan GMP Requirements: Practical ICH Area Differences & Healthcare ...
US, EU & Japan GMP Requirements: Practical ICH Area Differences & Healthcare ...
AudioEducator
 
Noor Mehar presentation
Noor Mehar presentationNoor Mehar presentation
Noor Mehar presentation
Kalim Ullah
 
Organizaton chart of us fda.
Organizaton chart of us fda.Organizaton chart of us fda.
Organizaton chart of us fda.
Rovil Goel
 
The Implications of Implementing the Directive on Falsified Medicines
The Implications of Implementing the Directive on Falsified MedicinesThe Implications of Implementing the Directive on Falsified Medicines
The Implications of Implementing the Directive on Falsified Medicines
European Industrial Pharmacists Group
 
Regulatory Agencies
Regulatory AgenciesRegulatory Agencies
Regulatory Agencies
hcpsgov
 
Analysing the EU PVG regulations
Analysing the EU PVG regulationsAnalysing the EU PVG regulations
Analysing the EU PVG regulations
Until ROI
 
pharmacovigilance set up poster
pharmacovigilance set up posterpharmacovigilance set up poster
pharmacovigilance set up poster
Priti Gupta
 
Big Data in Drug Safety: Making post-marketing surveillance in pharmacovigila...
Big Data in Drug Safety: Making post-marketing surveillance in pharmacovigila...Big Data in Drug Safety: Making post-marketing surveillance in pharmacovigila...
Big Data in Drug Safety: Making post-marketing surveillance in pharmacovigila...
Arete-Zoe, LLC
 
Australia_food-and-medicine-regulation
Australia_food-and-medicine-regulationAustralia_food-and-medicine-regulation
Australia_food-and-medicine-regulation
Parun Rutjanathamrong
 
PSM Interchange 2014 Panel 2: Linda Marks, Criminal Prosecutions: Patient Safety
PSM Interchange 2014 Panel 2: Linda Marks, Criminal Prosecutions: Patient SafetyPSM Interchange 2014 Panel 2: Linda Marks, Criminal Prosecutions: Patient Safety
PSM Interchange 2014 Panel 2: Linda Marks, Criminal Prosecutions: Patient Safety
The Partnership For Safe Medicines
 
A New Approach at Conducting Post-Market Drug Safety Surveillance
A New Approach at Conducting Post-Market Drug Safety SurveillanceA New Approach at Conducting Post-Market Drug Safety Surveillance
A New Approach at Conducting Post-Market Drug Safety Surveillance
Arete-Zoe, LLC
 
Biosimilars and Generics: A Comparison
Biosimilars and Generics: A Comparison      Biosimilars and Generics: A Comparison
Biosimilars and Generics: A Comparison
Joseph Pategou
 
Pharmaceutical Regulations Outline
Pharmaceutical Regulations Outline Pharmaceutical Regulations Outline
Pharmaceutical Regulations Outline
Obaid Ali / Roohi B. Obaid
 
EMEA
EMEAEMEA
EMEA
Gaurav Kr
 
Pharma Regulatory Affairs in Mexico
Pharma Regulatory Affairs in MexicoPharma Regulatory Affairs in Mexico
Pharma Regulatory Affairs in Mexico
María Inés Guaia
 
Pharma Uptoday Monthly Magazine Volume 5, Issue Aug 2014
Pharma Uptoday Monthly Magazine Volume 5, Issue Aug 2014Pharma Uptoday Monthly Magazine Volume 5, Issue Aug 2014
Pharma Uptoday Monthly Magazine Volume 5, Issue Aug 2014
Sathish Vemula
 
The FDA's Response to COVID - 19
The FDA's Response to COVID - 19The FDA's Response to COVID - 19
The FDA's Response to COVID - 19
EMMAIntl
 
Usfda sana 1
Usfda sana 1Usfda sana 1
Usfda sana 1
sanjay patil
 
Elisenda Perich, Health Innovation Conference 2021
Elisenda Perich, Health Innovation Conference 2021Elisenda Perich, Health Innovation Conference 2021
Elisenda Perich, Health Innovation Conference 2021
Starttech Ventures
 

What's hot (20)

Australia’s Response to COVID-19
Australia’s Response to COVID-19Australia’s Response to COVID-19
Australia’s Response to COVID-19
 
US, EU & Japan GMP Requirements: Practical ICH Area Differences & Healthcare ...
US, EU & Japan GMP Requirements: Practical ICH Area Differences & Healthcare ...US, EU & Japan GMP Requirements: Practical ICH Area Differences & Healthcare ...
US, EU & Japan GMP Requirements: Practical ICH Area Differences & Healthcare ...
 
Noor Mehar presentation
Noor Mehar presentationNoor Mehar presentation
Noor Mehar presentation
 
Organizaton chart of us fda.
Organizaton chart of us fda.Organizaton chart of us fda.
Organizaton chart of us fda.
 
The Implications of Implementing the Directive on Falsified Medicines
The Implications of Implementing the Directive on Falsified MedicinesThe Implications of Implementing the Directive on Falsified Medicines
The Implications of Implementing the Directive on Falsified Medicines
 
Regulatory Agencies
Regulatory AgenciesRegulatory Agencies
Regulatory Agencies
 
Analysing the EU PVG regulations
Analysing the EU PVG regulationsAnalysing the EU PVG regulations
Analysing the EU PVG regulations
 
pharmacovigilance set up poster
pharmacovigilance set up posterpharmacovigilance set up poster
pharmacovigilance set up poster
 
Big Data in Drug Safety: Making post-marketing surveillance in pharmacovigila...
Big Data in Drug Safety: Making post-marketing surveillance in pharmacovigila...Big Data in Drug Safety: Making post-marketing surveillance in pharmacovigila...
Big Data in Drug Safety: Making post-marketing surveillance in pharmacovigila...
 
Australia_food-and-medicine-regulation
Australia_food-and-medicine-regulationAustralia_food-and-medicine-regulation
Australia_food-and-medicine-regulation
 
PSM Interchange 2014 Panel 2: Linda Marks, Criminal Prosecutions: Patient Safety
PSM Interchange 2014 Panel 2: Linda Marks, Criminal Prosecutions: Patient SafetyPSM Interchange 2014 Panel 2: Linda Marks, Criminal Prosecutions: Patient Safety
PSM Interchange 2014 Panel 2: Linda Marks, Criminal Prosecutions: Patient Safety
 
A New Approach at Conducting Post-Market Drug Safety Surveillance
A New Approach at Conducting Post-Market Drug Safety SurveillanceA New Approach at Conducting Post-Market Drug Safety Surveillance
A New Approach at Conducting Post-Market Drug Safety Surveillance
 
Biosimilars and Generics: A Comparison
Biosimilars and Generics: A Comparison      Biosimilars and Generics: A Comparison
Biosimilars and Generics: A Comparison
 
Pharmaceutical Regulations Outline
Pharmaceutical Regulations Outline Pharmaceutical Regulations Outline
Pharmaceutical Regulations Outline
 
EMEA
EMEAEMEA
EMEA
 
Pharma Regulatory Affairs in Mexico
Pharma Regulatory Affairs in MexicoPharma Regulatory Affairs in Mexico
Pharma Regulatory Affairs in Mexico
 
Pharma Uptoday Monthly Magazine Volume 5, Issue Aug 2014
Pharma Uptoday Monthly Magazine Volume 5, Issue Aug 2014Pharma Uptoday Monthly Magazine Volume 5, Issue Aug 2014
Pharma Uptoday Monthly Magazine Volume 5, Issue Aug 2014
 
The FDA's Response to COVID - 19
The FDA's Response to COVID - 19The FDA's Response to COVID - 19
The FDA's Response to COVID - 19
 
Usfda sana 1
Usfda sana 1Usfda sana 1
Usfda sana 1
 
Elisenda Perich, Health Innovation Conference 2021
Elisenda Perich, Health Innovation Conference 2021Elisenda Perich, Health Innovation Conference 2021
Elisenda Perich, Health Innovation Conference 2021
 

Similar to Fda adverse event reporting requirements for otc drugs

Fda med watch
Fda med watchFda med watch
Fda med watch
Sridhar S
 
Fda guidance for pharmaceutical post marketing reporting professor pirouzi
Fda guidance for pharmaceutical post marketing reporting   professor pirouziFda guidance for pharmaceutical post marketing reporting   professor pirouzi
Fda guidance for pharmaceutical post marketing reporting professor pirouzi
Pharmaceutical Compliance Inspection unit, Crown College of Canada
 
Health Canada Progressive Licensing - Professor Peivand Pirouzi
Health Canada Progressive Licensing - Professor Peivand PirouziHealth Canada Progressive Licensing - Professor Peivand Pirouzi
Health Canada Progressive Licensing - Professor Peivand Pirouzi
Pharmaceutical Compliance Inspection unit, Crown College of Canada
 
Reporting adverse events under COVID-19 to FDA
Reporting adverse events under COVID-19 to FDAReporting adverse events under COVID-19 to FDA
Reporting adverse events under COVID-19 to FDA
Christine Zomorodian
 
Medwatch and FAERS database
Medwatch and FAERS databaseMedwatch and FAERS database
Medwatch and FAERS database
Dr. Ashish singh parihar
 
Pharma Uptoday Monthly Magazine - Volume 11, Issue Feb 2015
Pharma Uptoday Monthly Magazine - Volume 11, Issue Feb 2015Pharma Uptoday Monthly Magazine - Volume 11, Issue Feb 2015
Pharma Uptoday Monthly Magazine - Volume 11, Issue Feb 2015
Sathish Vemula
 
Usfda
UsfdaUsfda
US FDA
US FDA US FDA
US FDA
Suvarta Maru
 
How FSMA Changes The Status Quo For Food Businesses
How FSMA Changes The Status Quo For Food BusinessesHow FSMA Changes The Status Quo For Food Businesses
How FSMA Changes The Status Quo For Food Businesses
kmodza
 
Pharmaceutical product recall
Pharmaceutical product recallPharmaceutical product recall
Pharmaceutical product recall
Prandeep Borah
 
Spontaneous Reporting System
Spontaneous Reporting SystemSpontaneous Reporting System
Spontaneous Reporting System
Jasdeep singh brar
 
USFDA
USFDAUSFDA
Ppt 1 overview of regulatory affairs and diff bodies_august2016_final
Ppt 1 overview of regulatory affairs and diff bodies_august2016_finalPpt 1 overview of regulatory affairs and diff bodies_august2016_final
Ppt 1 overview of regulatory affairs and diff bodies_august2016_final
Rajashri Survase Ojha
 
My Presentation on Mexico Medical Device Regulations
My Presentation on Mexico Medical Device RegulationsMy Presentation on Mexico Medical Device Regulations
My Presentation on Mexico Medical Device Regulations
Harshit Thakkar
 
Labelling of drugs cosmetics nd biotech
Labelling of drugs cosmetics nd biotechLabelling of drugs cosmetics nd biotech
Labelling of drugs cosmetics nd biotech
Bindu Kshtriya
 
AN OVERVIEW AND IMPORTANCE OF PHARMACOVIGILANCE
AN OVERVIEW AND IMPORTANCE OF PHARMACOVIGILANCEAN OVERVIEW AND IMPORTANCE OF PHARMACOVIGILANCE
AN OVERVIEW AND IMPORTANCE OF PHARMACOVIGILANCE
Ramakrishna K
 
clinical Research and pharmacovigilance.pptx
clinical Research and pharmacovigilance.pptxclinical Research and pharmacovigilance.pptx
clinical Research and pharmacovigilance.pptx
Taranjum khan M.Pharmacy PHARMACOLOGY & TOXICOLOGY
 
US FDA Regs & Modernization Act 2012
US FDA Regs & Modernization Act 2012US FDA Regs & Modernization Act 2012
US FDA Regs & Modernization Act 2012
Asian Food Regulation Information Service
 
Pharmacovigilance sytem in United States of America (USA)
Pharmacovigilance sytem in United States of America (USA)Pharmacovigilance sytem in United States of America (USA)
Pharmacovigilance sytem in United States of America (USA)
PharmXL International Pvt. Ltd.
 
IQ Pharmacovigilance system (updated).pptx
IQ Pharmacovigilance system (updated).pptxIQ Pharmacovigilance system (updated).pptx
IQ Pharmacovigilance system (updated).pptx
Alaa Fadhel Hassan Alwazni
 

Similar to Fda adverse event reporting requirements for otc drugs (20)

Fda med watch
Fda med watchFda med watch
Fda med watch
 
Fda guidance for pharmaceutical post marketing reporting professor pirouzi
Fda guidance for pharmaceutical post marketing reporting   professor pirouziFda guidance for pharmaceutical post marketing reporting   professor pirouzi
Fda guidance for pharmaceutical post marketing reporting professor pirouzi
 
Health Canada Progressive Licensing - Professor Peivand Pirouzi
Health Canada Progressive Licensing - Professor Peivand PirouziHealth Canada Progressive Licensing - Professor Peivand Pirouzi
Health Canada Progressive Licensing - Professor Peivand Pirouzi
 
Reporting adverse events under COVID-19 to FDA
Reporting adverse events under COVID-19 to FDAReporting adverse events under COVID-19 to FDA
Reporting adverse events under COVID-19 to FDA
 
Medwatch and FAERS database
Medwatch and FAERS databaseMedwatch and FAERS database
Medwatch and FAERS database
 
Pharma Uptoday Monthly Magazine - Volume 11, Issue Feb 2015
Pharma Uptoday Monthly Magazine - Volume 11, Issue Feb 2015Pharma Uptoday Monthly Magazine - Volume 11, Issue Feb 2015
Pharma Uptoday Monthly Magazine - Volume 11, Issue Feb 2015
 
Usfda
UsfdaUsfda
Usfda
 
US FDA
US FDA US FDA
US FDA
 
How FSMA Changes The Status Quo For Food Businesses
How FSMA Changes The Status Quo For Food BusinessesHow FSMA Changes The Status Quo For Food Businesses
How FSMA Changes The Status Quo For Food Businesses
 
Pharmaceutical product recall
Pharmaceutical product recallPharmaceutical product recall
Pharmaceutical product recall
 
Spontaneous Reporting System
Spontaneous Reporting SystemSpontaneous Reporting System
Spontaneous Reporting System
 
USFDA
USFDAUSFDA
USFDA
 
Ppt 1 overview of regulatory affairs and diff bodies_august2016_final
Ppt 1 overview of regulatory affairs and diff bodies_august2016_finalPpt 1 overview of regulatory affairs and diff bodies_august2016_final
Ppt 1 overview of regulatory affairs and diff bodies_august2016_final
 
My Presentation on Mexico Medical Device Regulations
My Presentation on Mexico Medical Device RegulationsMy Presentation on Mexico Medical Device Regulations
My Presentation on Mexico Medical Device Regulations
 
Labelling of drugs cosmetics nd biotech
Labelling of drugs cosmetics nd biotechLabelling of drugs cosmetics nd biotech
Labelling of drugs cosmetics nd biotech
 
AN OVERVIEW AND IMPORTANCE OF PHARMACOVIGILANCE
AN OVERVIEW AND IMPORTANCE OF PHARMACOVIGILANCEAN OVERVIEW AND IMPORTANCE OF PHARMACOVIGILANCE
AN OVERVIEW AND IMPORTANCE OF PHARMACOVIGILANCE
 
clinical Research and pharmacovigilance.pptx
clinical Research and pharmacovigilance.pptxclinical Research and pharmacovigilance.pptx
clinical Research and pharmacovigilance.pptx
 
US FDA Regs & Modernization Act 2012
US FDA Regs & Modernization Act 2012US FDA Regs & Modernization Act 2012
US FDA Regs & Modernization Act 2012
 
Pharmacovigilance sytem in United States of America (USA)
Pharmacovigilance sytem in United States of America (USA)Pharmacovigilance sytem in United States of America (USA)
Pharmacovigilance sytem in United States of America (USA)
 
IQ Pharmacovigilance system (updated).pptx
IQ Pharmacovigilance system (updated).pptxIQ Pharmacovigilance system (updated).pptx
IQ Pharmacovigilance system (updated).pptx
 

More from ComplianceOnline

Sample ISO 13485 Quality Manual & Procedures Package
Sample ISO 13485 Quality Manual & Procedures Package Sample ISO 13485 Quality Manual & Procedures Package
Sample ISO 13485 Quality Manual & Procedures Package
ComplianceOnline
 
Enterprise risk management
Enterprise risk managementEnterprise risk management
Enterprise risk management
ComplianceOnline
 
Analytical Instrument Qualification and System Validation
Analytical Instrument Qualification and System ValidationAnalytical Instrument Qualification and System Validation
Analytical Instrument Qualification and System Validation
ComplianceOnline
 
HR Audits: A Critical Compliance Process
HR Audits: A Critical Compliance ProcessHR Audits: A Critical Compliance Process
HR Audits: A Critical Compliance Process
ComplianceOnline
 
Medical Devices: EU Directives, Guidance Documents, CE Marking Process and IS...
Medical Devices: EU Directives, Guidance Documents, CE Marking Process and IS...Medical Devices: EU Directives, Guidance Documents, CE Marking Process and IS...
Medical Devices: EU Directives, Guidance Documents, CE Marking Process and IS...
ComplianceOnline
 
IFRS Revenue Recognition - how to do it
IFRS Revenue Recognition - how to do itIFRS Revenue Recognition - how to do it
IFRS Revenue Recognition - how to do it
ComplianceOnline
 
Drug Master Files (DMFs) - Understanding and Meeting Your Global Regulatory a...
Drug Master Files (DMFs) - Understanding and Meeting Your Global Regulatory a...Drug Master Files (DMFs) - Understanding and Meeting Your Global Regulatory a...
Drug Master Files (DMFs) - Understanding and Meeting Your Global Regulatory a...
ComplianceOnline
 
Design Validation Protocol and Acceptance Criteria for Chromatographic Method...
Design Validation Protocol and Acceptance Criteria for Chromatographic Method...Design Validation Protocol and Acceptance Criteria for Chromatographic Method...
Design Validation Protocol and Acceptance Criteria for Chromatographic Method...
ComplianceOnline
 
Recalls of Medical Devices in the US
Recalls of Medical Devices in the USRecalls of Medical Devices in the US
Recalls of Medical Devices in the US
ComplianceOnline
 
ComplianceOnline Virtual Seminar - IFRS and Effective Fraud Prevention Strate...
ComplianceOnline Virtual Seminar - IFRS and Effective Fraud Prevention Strate...ComplianceOnline Virtual Seminar - IFRS and Effective Fraud Prevention Strate...
ComplianceOnline Virtual Seminar - IFRS and Effective Fraud Prevention Strate...
ComplianceOnline
 
IFRS Financial Instruments – how to comply with changing requirements
IFRS Financial Instruments – how to comply with changing requirementsIFRS Financial Instruments – how to comply with changing requirements
IFRS Financial Instruments – how to comply with changing requirements
ComplianceOnline
 

More from ComplianceOnline (11)

Sample ISO 13485 Quality Manual & Procedures Package
Sample ISO 13485 Quality Manual & Procedures Package Sample ISO 13485 Quality Manual & Procedures Package
Sample ISO 13485 Quality Manual & Procedures Package
 
Enterprise risk management
Enterprise risk managementEnterprise risk management
Enterprise risk management
 
Analytical Instrument Qualification and System Validation
Analytical Instrument Qualification and System ValidationAnalytical Instrument Qualification and System Validation
Analytical Instrument Qualification and System Validation
 
HR Audits: A Critical Compliance Process
HR Audits: A Critical Compliance ProcessHR Audits: A Critical Compliance Process
HR Audits: A Critical Compliance Process
 
Medical Devices: EU Directives, Guidance Documents, CE Marking Process and IS...
Medical Devices: EU Directives, Guidance Documents, CE Marking Process and IS...Medical Devices: EU Directives, Guidance Documents, CE Marking Process and IS...
Medical Devices: EU Directives, Guidance Documents, CE Marking Process and IS...
 
IFRS Revenue Recognition - how to do it
IFRS Revenue Recognition - how to do itIFRS Revenue Recognition - how to do it
IFRS Revenue Recognition - how to do it
 
Drug Master Files (DMFs) - Understanding and Meeting Your Global Regulatory a...
Drug Master Files (DMFs) - Understanding and Meeting Your Global Regulatory a...Drug Master Files (DMFs) - Understanding and Meeting Your Global Regulatory a...
Drug Master Files (DMFs) - Understanding and Meeting Your Global Regulatory a...
 
Design Validation Protocol and Acceptance Criteria for Chromatographic Method...
Design Validation Protocol and Acceptance Criteria for Chromatographic Method...Design Validation Protocol and Acceptance Criteria for Chromatographic Method...
Design Validation Protocol and Acceptance Criteria for Chromatographic Method...
 
Recalls of Medical Devices in the US
Recalls of Medical Devices in the USRecalls of Medical Devices in the US
Recalls of Medical Devices in the US
 
ComplianceOnline Virtual Seminar - IFRS and Effective Fraud Prevention Strate...
ComplianceOnline Virtual Seminar - IFRS and Effective Fraud Prevention Strate...ComplianceOnline Virtual Seminar - IFRS and Effective Fraud Prevention Strate...
ComplianceOnline Virtual Seminar - IFRS and Effective Fraud Prevention Strate...
 
IFRS Financial Instruments – how to comply with changing requirements
IFRS Financial Instruments – how to comply with changing requirementsIFRS Financial Instruments – how to comply with changing requirements
IFRS Financial Instruments – how to comply with changing requirements
 

Fda adverse event reporting requirements for otc drugs

  • 1. FDA Notificationsand Medwatch Form Requirements Adverse Event Reporting for OTC Drugs and Dietary Supplements
  • 2. The Background– What YouNeedto Know Adverse Event (AE) reporting regulations implement the Dietary Supplement & OTC Drug Consumer Protection Act of 2006 (Public Law 109-462). FDA regulations for adverse event reporting went into effect in December 2007. Product label must contain the address (street address or P.O. Box) or phone number at which company or other responsible person will receive a serious adverse event report. Serious Adverse Event (SAE) reporting is required for all OTC Drugs and Dietary Supplements.
  • 3. Products That Are Covered All OTC monographed drugs (Rx to OTC drugs are already required to report AEs). All dietary supplements including vitamins, minerals, herbal or other botanical products, amino acids, or any dietary substance used to supplement the diet by increasing the total dietary intake. When the Personal Care Products Safety Act becomes law, cosmetics will also be covered.
  • 4. Death: Report if the patient’s death is suspected of being associated with use of the product by the patient. Life-Threatening: Report if the person was at substantial risk of dying at time of the adverse event or if suspected that continued use of product could result in a person’s death. Hospitalization: Report if admission to the hospital was caused by or related to an adverse event associated with use of the product. Emergency Room treatment is sometimes reported too. Disability: Report if the adverse event resulted in a significant or permanent change, impairment or damage to the person’s body function/structure or quality of life. Spontaneous abortion, congenital anomaly or birth defect associated with a product use must also be reported to the FDA. Definition of a Serious Adverse Event (SAE) Section 761(a)(2) of the F,D, & C Act
  • 5. FDA Notifications- Voluntary SAE Reporting FDA encourages healthcare professionals to report serious adverse events to the agency for tracking purposes. FDA’s Center for Food Safety & Applied Nutrition (CFSAN) Adverse Event Reporting System (CAERS) collects reports about adverse events and product complaints related to CFSAN regulated products, including foods, dietary supplements and cosmetics. CFSAN encourages voluntary AE reports for cosmetics and conventional foods. If a company receives a report of a serious adverse event, you should report it to CAERS even if reporting isn’t mandatory for the product (e.g. a food or cosmetic).
  • 6. FDA Notifications Many serious adverse events are reported to FDA directly by consumers, hospitals, or healthcare professionals. If FDA receives a serious adverse event report about a company’s product they will contact you and you must keep that report on file. Often FDA notification comes with a request for more information and submission of a Medwatch form with product label.
  • 7. MedwatchFormRequirements(Form 3500A) Medwatch form must identify the injured person (name, age, sex, full address, etc.). Initials are used to protect privacy. An identifiable initial reporter of the event. Identity and contact information for the responsible party (i.e. the manufacturer, packer, or distributor representative submitting the AE report to FDA). Name of the specific product that is suspected of causing the adverse event (not just a brand name). Description of the serious adverse event with outcome.
  • 8. Address for MedwatchFormHard Copy Submission DIETARY SUPPLEMENTS: FAX NUMBER FOR ALL AEs: 1 800 332 - 0178 FDA Center Food Safety & Nutrition Office of Food Defense, HFS -11 5100 Paint Brach Parkway College Park, MD. 20740 OTC DRUGS: FDA Center Drug Evaluation & Research Central Document Room 5901-B Ammendale Road Beltsville, MD. 20705-1266
  • 9. Online Reportingof MedwatchForms Or http://www.fda.gov/Safety/MedWatch/default.htm Go to the FDA website (www.fda.gov), click on “Drugs” and enter “MEDWATCH form”. Click on “Download form” or click on “Recalls & Alerts” and see bullet called “MEDWATCH.” Click on “Report serious adverse events online.”